Loading...
•
Jun 30, 2025
Tempus AI Inc Q2 2025 Earnings Report
Tempus AI reported strong Q2 2025 growth, driven by triple-digit genomics revenue expansion and improved margins, despite posting a net loss.
Key Takeaways
Tempus AI delivered Q2 2025 revenue of $314.6M, up 89.6% year-over-year, with significant growth in genomics and improved gross margin. The company narrowed its net loss compared to last year and continued to expand AI-driven healthcare tools.
Revenue surged 89.6% YoY to $314.6M.
Genomics revenue grew 115.3% YoY to $241.8M.
Gross profit rose 158.3% YoY to $195.0M with a 62.0% gross margin.
Net loss improved to $42.8M from $552.2M last year.
Revenue by Segment
Forward Guidance
Tempus increased its full-year 2025 guidance, expecting approximately $1.26B in revenue and positive adjusted EBITDA of $5M.
Positive Outlook
- Full-year 2025 revenue guidance raised to $1.26B.
- Expecting positive adjusted EBITDA of $5M in 2025.
- Genomics and hereditary testing volumes showing strong double-digit growth.
- Expanded AI-powered clinical tools across oncology.
- Strengthened balance sheet with $750M in convertible senior notes.
Challenges Ahead
- Continued net loss despite revenue growth.
- Significant interest expense from new debt issuance.
- Ongoing high stock-based compensation costs.
- Adjusted EBITDA remains negative for the quarter.
- High R&D and SG&A expenses impacting profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...